TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Renal graft outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in modified Rankin score (mRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of lesions achieving 50% reduction in greatest diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Application Site Reactions (ASRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Review of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall-Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: occurrence of pressure injury
Endpoint domain: Adverse events/effects
Primary endpoint: Change in UCP1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased pharmacologically treated NOWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year-relapsed free survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Amino acid catabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to dietary tracking
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to dietary goals
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Evaluation of quality of life using the SF-12 life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perioperative Opioid Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality of kidney transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Zonulin levels in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Extracellular Volume (ECV) of Myocardial Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCtau,ss of D352(Part 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau,ss of D794(Part 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of D352(Part 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of D794(Part 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Purulent Rhinitis Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in understanding how to use a power wheelchair
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in power wheelchair skill performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of developing antibiotic resistance
Endpoint domain: Adverse events/effects
Primary endpoint: Development of gout
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure rehospitalization within 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine output up to 48 hours after treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acceptability Assessed Via Qualitative Exit Interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment acceptability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Investigators Global Assessment Score of 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of Selinexor
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical, laboratory and imaging biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in annual relapse rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline daily life gait performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermittent work performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change of intensive care unit acquired weakness (ICUAW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of USE in characterization of solitary thyroid nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Assessment of risk of malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Muscle fiber cross-sectional area and fiber type proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in dyspnea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concentration of serum FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of serum AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for Paris classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke and systemic embolic events
Endpoint domain: Mortality/survival
Primary endpoint: Change in Surgical Fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Myocardial injury after non cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Balance Error Scoring System (BESS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutation rate of ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent Attitudes about Childhood Vaccines (PACV-4 scale) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of eligible patients matched for transplant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Valve growth following partial heart transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major pathological response (MPR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade 3 or Higher Treatment-Related Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Disease progression risk in PSC patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of PrEP and OAT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Persistence on PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Self Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in FIX activity from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck Bournemouth Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Beta-D-Glucagon levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short-chain fatty acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free amino acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of the Ark in facilitating cannulation of AVFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of the Ark
Endpoint domain: Adverse events/effects
Primary endpoint: Change in measured glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in urinary Kidney Injury Molecule 1 (KIM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Asymptomatic prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and Grade of Solicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in frequency of (re-)victimization
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Dynamic Gait Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural similarity at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction success of change in smoking from surveys
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of craving ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term HPV type-specific antibody response for type HPV-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short-term HPV type-specific antibody response for type HPV-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short-term HPV type-specific antibody response for type HPV-16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short-term HPV type-specific antibody response for type HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short-term HPV type-specific antibody response for type HPV-31
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in secondary stability of dental implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Time of rescue analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correct identification of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Fat Attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat-phobia scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight Implicit Association Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Reported Spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Temperature vs Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Clobetasol propionate ophthalmic nanoemulsion
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in IHS4 over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite rate of all-cause mortality and stroke with disability
Endpoint domain: Mortality/survival
Primary endpoint: Awareness of risk of unwanted pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of SARS-CoV-2 antigen in nasal swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate for cPOCUS Exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of mRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Visual Acuity (VA) with study lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pectoralis Minor Length Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Passive Shoulder Internal Rotation (IR) and External Rotation (ER) Mobility Flexibility Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Active Shoulder IR and ER Mobility Flexibility Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Resolution of plane warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: FT patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of significant patterns of Acanthamoeba infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HPV16 neutralizing antibody geometric mean titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance of the side-to-side anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Iodine-123 uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Freedom from device- and procedure-related Subsequent Surgical Interventions
Endpoint domain: Adverse events/effects
Primary endpoint: abdominal respiratory motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: gastrointestinal motility motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inter-fractional motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of medical and surgical complications within 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of BC-Navi
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chemotherapy Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain AD pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Any fatal or non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Time to first protocol-defined relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement: Enactment of treatment skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Physical domain subscale of the Oxford Ankle Foot Questionnaire for Children (OxAFQ-C)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area under the glucose infusion rate-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Persistent Post Concussion Symptoms (PPCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Serum Ferritin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of solicited local and systemic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number, severity, and relatedness of clinically significant hematological and biochemical measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number, severity and relatedness of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral Microbleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Maximal isometric muscle strength of the quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean of the 3 overnight reaction time reciprocal of the psychomotor vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of the 3 overnight number of lapses in psychomotor vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of the 3 overnight number of false starts in the psychomotor vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of the 3 overnight Aggregate Scores of the psychomotor vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of the 3 overnight Stanford Sleepiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Complete hematological remission (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-reported tobacco cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lower extremity independence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ramipril, ramiprilat and hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72 of ramipril, ramiprilat and hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Disease Activity Score 28 (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose interruptions, reductions, and treatment terminations due to AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time to achieve secure grasp upon initial contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete pick-up and placement of object
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of FAST in detecting intraperitoneal free fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour ambulatory systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG-based Neuromarker Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Paid employment status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change of MRI whole brain cerebrovascular reactivity (wbCVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean time to arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse wave velocity (carotid-femoral)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of the most severe modified WHO Mucositis Grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upper extremity disability level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in persistent Genital HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in geometric titers for HPV-specific Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B-memory cell elicitation in the participants given a booster vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bayley Scale of Infant and Toddler Development, Fourth Edition (BSID-4)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vineland 3
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Achievement of ≥5% weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in EEG Power at 40 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patients Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adapted Sexual Self-efficacy Erectile Tool
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Short Warwick-Edinburgh Mental Wellbeing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Brunnsviken Brief Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The Self-compassion Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic performance of CONVIVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of aging biomarkers' values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sternal healing effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC0-∞ of NNC0194-0499 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Serum Semaphorin 4A Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrospinal Fluid Semaphorin 4A Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical improvements in mild cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical improvements in moderate cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity of vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency of PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes